LDL-cholesterol lowering: timing is everything Authors: Alexander C Razavi, Roger S Blumenthal Published: 2026 Legendary golfer Arnold Palmer once stated that “Timing is everything in life and in golf”; now we have more evidence that it also applies to Preventive Cardiology. Low-density lipoprotein-cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease. Approximately one-half of adults have LDL-C ≥ 100 mg/dL [1], with an estimated 1 in 250–300 experiencing levels ≥ 190 mg/dL consistent with heterozygous familial hypercholesterolemia (FH) [2]. While there have been population-wide improvements in mean LDL-C and statin utilization, such improvements have stalled in the post coronavirus 2019 pandemic era and we now have a renewed focus on early LDL-C control as outlined in the practice-changing 2026 American College of Cardiology (ACC)/American Heart Association (AHA)/Multisociety Dyslipidemia Guideline [3]. In this issue of the American Journal of Preventive Cardiology, Ray and colleagues performed a systematic review and analysis of 17 randomized controlled trials (n = 105,879 participants, median follow-up 4.4 years) to 1) compare the relative risk reduction (RRR) for major adverse cardiovascular events (MACE) per unit of lowering of LDL-C among individuals with no or a low prevalence of ASCVD, and 2) approximate the LDL-C reduction required to achieve a 25% RRR [4]. The RRR for MACE varied by baseline ASCVD risk with a higher RRR observed for trials with lower baseline placebo event rates (<1%/year: 39% RRR, 1-<2%/year: 34%, 2–6%/year: 18%, ≥6%/year: 17%). A similar pattern was observed for the absolute LDL-C required to provide a 25% RRR, with higher levels of LDL-C reduction required for those at higher baseline risk. Individuals with <2% annualized MACE risk had 25% RRR with ∼25 mg/dL lowering of LDL-C, whereas a two-fold higher LDL-C reduction (∼50 mg/dL) was required for those with annualized MACE risk ≥ 2%. This study by Ray et al. demonstrating an inverse association between MACE RRR for LDL-C lowering and baseline ASCVD risk underlines the proof of concept that LDL-C lowering is likely beneficial even in many low-risk patients. These findings emphasize the life course approach to LDL-C control and importance of engaging in such discussions very early on with patients, similar to the approach for hypertension, weight management, and type 2 diabetes prevention. The lower RRR per LDL-C lowering in those with higher baseline ASCVD risk does not suggest that LDL-C control is unimportant in this patient population, but that a multimodal risk reduction strategy that additionally targets non-lipid pathways is critical in higher risk individuals. The current analysis should be interpreted in appropriate clinical context. While there is a dose-dependent relationship between LDL-C and ASCVD risk, there are nuances in everyday clinical practice with respect to patient preferences and heterogeneity in risk, which are emphasized in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline [3]. Some low-borderline risk patients may prefer to first focus on lifestyle adjustments for LDL-C control for a year or more, which is reasonable especially for those with absolute 10-year risk <5% calculated by the PREVENT (American Heart Association Predicting Risk of Cardiovascular Disease [CVD] Events) equations. Dietary patterns with a high intake of fiber (fruits, vegetables, legumes, whole grains) and that minimize saturated fat (red meat, butter, whole milk, tropical oils) and replace with mono/polyunsaturated fat intake (nuts, fish) are associated with lower LDL-C levels. This approach is analogous to a guideline recommended 3 to 6-month interval of lifestyle adjustments to lower blood pressure in adults with hypertension without clinical CVD and with a 10-year PREVENT CVD risk <7.5%, prior to considering pharmacotherapy [5]. The RRR of LDL-C lowering with patients should always be discussed in context of short-term and long-term absolute risk when considering primary prevention pharmacotherapy. Given the considerably high prevalence of elevated LDL-C and differing patient preferences on treatment decisions, pharmacotherapy for all individuals with hypercholesterolemia may not be an attainable goal despite the large projected public health benefits. As such, there is a need to identify the highest risk subgroups of patients to guide the optimal timing for initiating LDL-C lowering pharmacotherapy for primary prevention (Table 1). Table 1Adults without clinical ASCVD who derive the largest benefit from statin therapy and LDL-C control.Table 1 dummy alt textSubgroupRecommendationFamilial Hypercholesterolemia (LDL-C ≥ 190 mg/dL)Class 1Type 2 DiabetesCKD Stage 3 or HigherPrevalent CAC, especially ≥75th percentile or ≥100 AU10-Year PREVENT CVD ≥10%HIVLDL-C ≥ 160 mg/dLClass 2a10-Year PREVENT CVD 3–10%, especially in the presence of risk enhancers*30-Year PREVENT CVD ≥10%⁎Family history of premature ASCVD, high risk ancestry (e.g. South Asian or Filipino), high polygenic risk, chronic inflammatory diseases (systemic lupus, rheumatoid arthritis, advanced psoriasis, inflammatory arthritis), Lp(a) ≥125 nmol/L or ≥50 mg/dL, hsCRP ≥2 mg/L on >1 occasion, persistently elevated triglycerides ≥175 mg/dL (non-fasting) or ≥150 mg/dL (fasting), cardiovascular kidney metabolic syndrome, persistently elevated LDL-C ≥ 160 mg/dL, non-HDL-C ≥ 190 mg/dL or apolipoprotein-B ≥ 120 mg/dL, reproductive risk markers. Adults without clinical ASCVD who derive the largest benefit from statin therapy and LDL-C control. Family history of premature ASCVD, high risk ancestry (e.g. South Asian or Filipino), high polygenic risk, chronic inflammatory diseases (systemic lupus, rheumatoid arthritis, advanced psoriasis, inflammatory arthritis), Lp(a) ≥125 nmol/L or ≥50 mg/dL, hsCRP ≥2 mg/L on >1 occasion, persistently elevated triglycerides ≥175 mg/dL (non-fasting) or ≥150 mg/dL (fasting), cardiovascular kidney metabolic syndrome, persistently elevated LDL-C ≥ 160 mg/dL, non-HDL-C ≥ 190 mg/dL or apolipoprotein-B ≥ 120 mg/dL, reproductive risk markers. The JUPITER (Justification for the Use of Statins in Prevention) trial demonstrated a 44% RRR (absolute risk reduction [ARR] of 1.2% at a median of 1.9 years of follow-up) in ASCVD with rosuvastatin 20 mg for individuals with LDL-C < 130 mg/dL and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/dL [6]. Similarly, the REPRIEVE (Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus [HIV]) found a 35% RRR (ARR of 2.5%) over 5 years with pitavastatin 4 mg among persons with HIV, but with a 10-year ASCVD risk <15% by the 2013 Pooled Cohort Equations [7]. Results from JUPITER and REPRIEVE suggest that initiation of statin therapy are reasonable for individuals with elevated hsCRP (Class 2a recommendation) and recommended for those with HIV (Class 1 recommendation) [3]. A prior meta-analysis on the benefits of LDL-C lowering in primary prevention by Kalra et al. [8] found that individuals with inflammatory conditions had among the largest RRR per LDL-C lowering, further supporting findings observed in JUPITER and REPRIEVE. Beyond inflammation, post-hoc analyses in JUPITER have demonstrated that statin therapy lowers ASCVD risk among individuals with elevated lipoprotein(a) [Lp(a)], of whom have residual risk despite LDL-C control due to the absence of Lp(a)-lowering effect of statins [9]. In this context, bundled measurement of LDL-C, Lp(a), and hsCRP has been proposed to guide risk assessment, statin eligibility, and non-statin therapy across the spectrum of ASCVD risk [10]. In addition to biomarkers, measurement of coronary artery calcium (CAC) on non-contrast cardiac computed tomography (CT) is an integral component to identify individuals with borderline-intermediate risk who derive maximal benefit from statin therapy and guide the intensity of LDL-C lowering. Modeling studies in observational cohorts of statin eligible individuals consistently demonstrate that the estimated number needed to treat is approximately 2 to 4-fold lower for those with versus without CAC [11,12]. A primary focus of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline is a life course approach to LDL-C control [3]. Screening for FH and lipid disorders should begin as early as 9–11 years old and all adults ≥18 years old should have had an initial lipid profile and once-per-lifetime Lp(a) testing. Formal ASCVD risk assessment via the PREVENT equations can begin at age 30, enabling calculation of short-term and long-term (30-year) risk to guide eligibility for residual risk assessment, subclinical atherosclerosis testing, and ultimately statin pharmacotherapy. This approach is practical to facilitate optimal LDL-C control for the prevention of ASCVD at the patient and population-levels. In summary, Ray et al. have demonstrated that timing is as important in Preventive Cardiology as it is in golf. CRediT authorship contribution statement Alexander C. Razavi: Writing – original draft, Writing – review & editing. Roger S. Blumenthal: Supervision, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. References